Torsade B
de I
pointes I
ventricular B
tachycardia I
during O
low O
dose O
intermittent O
dobutamine O
treatment O
in O
a O
patient O
with O
dilated B
cardiomyopathy I
and O
congestive B
heart I
failure I
. O

Torsade B
de I
pointes I
ventricular B
tachycardia I
during O
low O
dose O
intermittent O
dobutamine O
treatment O
in O
a O
patient O
with O
dilated B
cardiomyopathy I
and O
congestive B
heart I
failure I
. O

The O
authors O
describe O
the O
case O
of O
a O
56 O
- O
year O
- O
old O
woman O
with O
chronic O
, O
severe O
heart B
failure I
secondary O
to O
dilated B
cardiomyopathy I
and O
absence O
of O
significant O
ventricular B
arrhythmias I
who O
developed O
QT B
prolongation I
and O
torsade B
de I
pointes I
ventricular B
tachycardia I
during O
one O
cycle O
of O
intermittent O
low O
dose O
( O
2 O
. O
5 O
mcg O
/ O
kg O
per O
min O
) O
dobutamine O
. O

This O
report O
of O
torsade B
de I
pointes I
ventricular B
tachycardia I
during O
intermittent O
dobutamine O
supports O
the O
hypothesis O
that O
unpredictable O
fatal O
arrhythmias B
may O
occur O
even O
with O
low O
doses O
and O
in O
patients O
with O
no O
history O
of O
significant O
rhythm O
disturbances O
. O

After O
angiography O
by O
the O
venous O
route O
in O
patient O
n O
degree O
1 O
a O
biphasic O
reaction O
with O
an O
immediate O
reaction O
( O
dyspnea B
, O
loss B
of I
consciousness I
) O
and O
delayed O
macro B
- I
papular I
rash I
appeared O
, O
whilst O
patient O
n O
degree O
2 O
developed O
a O
generalised O
sensation O
of O
heat O
, O
persistent O
pain B
at O
the O
site O
of O
injection O
immediately O
and O
a O
generalised O
macro O
- O
papular O
reaction O
after O
24 O
hours O
. O

Prolonged O
left B
ventricular I
dysfunction I
occurs O
in O
patients O
with O
coronary B
artery I
disease I
after O
both O
dobutamine O
and O
exercise O
induced O
myocardial B
ischaemia I
. O

Prolonged O
left B
ventricular I
dysfunction I
occurs O
in O
patients O
with O
coronary B
artery I
disease I
after O
both O
dobutamine O
and O
exercise O
induced O
myocardial B
ischaemia I
. O

OBJECTIVE O
: O
To O
determine O
whether O
pharmacological O
stress O
leads O
to O
prolonged O
but O
reversible O
left B
ventricular I
dysfunction I
in O
patients O
with O
coronary B
artery I
disease I
, O
similar O
to O
that O
seen O
after O
exercise O
. O

OBJECTIVE O
: O
To O
determine O
whether O
pharmacological O
stress O
leads O
to O
prolonged O
but O
reversible O
left B
ventricular I
dysfunction I
in O
patients O
with O
coronary B
artery I
disease I
, O
similar O
to O
that O
seen O
after O
exercise O
. O

SUBJECTS O
: O
10 O
patients O
with O
stable B
angina I
, O
angiographically O
proven O
coronary B
artery I
disease I
, O
and O
normal O
left O
ventricular O
function O
. O

CONCLUSIONS O
: O
In O
patients O
with O
coronary B
artery I
disease I
, O
dobutamine O
induced O
ischaemia B
results O
in O
prolonged O
reversible O
left B
ventricular I
dysfunction I
, O
presumed O
to O
be O
myocardial B
stunning I
, O
similar O
to O
that O
seen O
after O
exercise O
. O

CONCLUSIONS O
: O
In O
patients O
with O
coronary B
artery I
disease I
, O
dobutamine O
induced O
ischaemia B
results O
in O
prolonged O
reversible O
left B
ventricular I
dysfunction I
, O
presumed O
to O
be O
myocardial B
stunning I
, O
similar O
to O
that O
seen O
after O
exercise O
. O

Dobutamine O
induced O
ischaemia B
could O
therefore O
be O
used O
to O
study O
the O
pathophysiology O
of O
this O
phenomenon O
further O
in O
patients O
with O
coronary B
artery I
disease I
. O

BACKGROUND O
: O
The O
use O
of O
appetite O
suppressants O
in O
Europe O
has O
been O
associated O
with O
the O
development O
of O
primary B
pulmonary I
hypertension I
( O
PPH B
) O
. O

RESULTS O
: O
The O
patient O
had O
episodic O
deterioration O
of O
vision O
in O
both O
eyes O
, O
with O
clinical O
features O
resembling O
ischemic B
optic I
neuropathies I
. O

Deterioration B
of I
vision I
occurred O
despite O
discontinuation O
of O
the O
tacrolimus O
. O

CONCLUSION O
: O
Tacrolimus O
and O
other O
immunosuppressive O
agents O
may O
be O
associated O
with O
optic B
nerve I
toxicity I
. O

The O
aim O
of O
the O
study O
was O
to O
evaluate O
the O
potential O
role O
for O
a O
selective O
alpha1 O
- O
adrenoceptor O
agonist O
in O
the O
treatment O
of O
urinary B
stress I
incontinence I
. O

A O
group O
of O
doctors O
in O
Boston O
warn O
that O
the O
protease O
inhibitor O
Viracept O
may O
cause O
an O
irregular B
heart I
beat I
, O
known O
as O
bradycardia B
, O
in O
people O
with O
HIV O
. O

Frequency O
of O
appearance O
of O
myeloperoxidase O
- O
antineutrophil O
cytoplasmic O
antibody O
( O
MPO O
- O
ANCA O
) O
in O
Graves B
' I
disease I
patients O
treated O
with O
propylthiouracil O
and O
the O
relationship O
between O
MPO O
- O
ANCA O
and O
clinical O
manifestations O
. O

OBJECTIVE O
: O
Myeloperoxidase O
antineutrophil O
cytoplasmic O
antibody O
( O
MPO O
- O
ANCA O
) O
- O
positive O
vasculitis B
has O
been O
reported O
in O
patients O
with O
Graves B
' I
disease I
who O
were O
treated O
with O
propylthiouracil O
( O
PTU O
) O
. O

Nevertheless O
, O
there O
have O
been O
no O
studies O
on O
the O
temporal O
relationship O
between O
the O
appearance O
of O
MPO O
- O
ANCA O
and O
vasculitis B
during O
PTU O
therapy O
, O
or O
on O
the O
incidence O
of O
MPO O
- O
ANCA O
in O
untreated O
Graves B
' I
disease I
patients O
. O

Therefore O
, O
we O
sought O
to O
address O
these O
parameters O
in O
patients O
with O
Graves B
' I
disease I
. O

PATIENTS O
: O
We O
investigated O
102 O
untreated O
patients O
with O
hyperthyroidism B
due O
to O
Graves B
' I
disease I
for O
the O
presence O
of O
MPO O
- O
ANCA O
, O
and O
for O
the O
development O
vasculitis B
after O
starting O
PTU O
therapy O
. O

RESULTS O
: O
Before O
treatment O
, O
the O
MPO O
- O
ANCA O
titres O
of O
all O
102 O
untreated O
Graves B
' I
disease I
patients O
were O
within O
the O
reference O
range O
( O
below O
10 O
U O
/ O
ml O
) O
. O

Findings O
consistent O
with O
coronary B
artery I
disease I
were O
detected O
in O
12 O
( O
34 O
% O
) O
patients O
and O
3 O
( O
9 O
% O
) O
controls O
( O
p O
= O
0 O
. O
01 O
) O
. O

BACKGROUND O
: O
This O
study O
examined O
the O
role O
of O
phase O
2 O
early O
afterdepolarization O
( O
EAD O
) O
in O
producing O
a O
trigger O
to O
initiate O
torsade B
de I
pointes I
( O
TdP B
) O
with O
QT B
prolongation I
induced O
by O
dl O
- O
sotalol O
and O
azimilide O
. O

Low B
back I
pain I
was O
also O
relieved O
by O
both O
drugs O
. O

We O
report O
three O
cases O
of O
severe O
hypoxaemia B
after O
ibuprofen O
administration O
during O
a O
randomised O
controlled O
trial O
of O
prophylactic O
treatment O
of O
patent B
ductus I
arteriosus I
with O
ibuprofen O
in O
premature O
infants O
born O
at O
less O
than O
28 O
weeks O
of O
gestation O
. O

Persistent O
sterile O
leukocyturia B
is O
associated O
with O
impaired B
renal I
function I
in O
human B
immunodeficiency I
virus I
type I
1 I
- I
infected I
children O
treated O
with O
indinavir O
. O

A O
50 O
- O
year O
- O
old O
patient O
admitted O
to O
our O
hospital O
for O
fever B
and O
acute B
renal I
failure I
. O

Before O
admission O
, O
he O
had O
been O
taking O
nicergoline O
and O
bendazac O
lysine O
due O
to O
retinal B
vein I
occlusion I
at O
ophthalmologic O
department O
. O

Neuroleptic B
malignant I
syndrome I
complicated O
by O
massive O
intestinal O
bleeding B
in O
a O
patient O
with O
chronic B
renal I
failure I
. O

Neuroleptic B
malignant I
syndrome I
complicated O
by O
massive O
intestinal O
bleeding B
in O
a O
patient O
with O
chronic B
renal I
failure I
. O

A O
patient O
with O
chronic B
renal I
failure I
( O
CRF B
) O
developed O
neuroleptic B
malignant I
syndrome I
( O
NMS B
) O
after O
administration O
of O
risperidone O
and O
levomepromazine O
. O

A O
patient O
with O
chronic B
renal I
failure I
( O
CRF B
) O
developed O
neuroleptic B
malignant I
syndrome I
( O
NMS B
) O
after O
administration O
of O
risperidone O
and O
levomepromazine O
. O

Evidence O
of O
peripheral B
sensory I
neuropathy I
was O
found O
in O
nine O
of O
13 O
men O
before O
treatment O
. O

We O
describe O
2 O
cases O
of O
grand B
mal I
seizures I
following O
accidental O
intravascular O
injection O
of O
levobupivacaine O
. O

Immediately O
after O
the O
administration O
of O
levobupivacaine O
0 O
. O
5 O
% O
with O
epinephrine O
2 O
. O
5 O
microgram O
/ O
mL O
, O
the O
patients O
developed O
grand B
mal I
seizures I
, O
despite O
negative O
aspiration O
for O
blood O
and O
no O
clinical O
signs O
of O
intravenous O
epinephrine O
administration O
. O

Amiodarone O
- O
induced O
torsade B
de I
pointes I
during O
bladder O
irrigation O
: O
an O
unusual O
presentation O
- O
- O
a O
case O
report O
. O

The O
authors O
present O
a O
case O
of O
early O
( O
within O
4 O
days O
) O
development O
of O
torsade B
de I
pointes I
( O
TdP B
) O
associated O
with O
oral O
amiodarone O
therapy O
. O

Myotonia B
congenita I
( O
MC B
) O
is O
caused O
by O
a O
defect O
in O
the O
skeletal O
muscle O
chloride O
channel O
function O
, O
which O
may O
cause O
sustained B
membrane I
depolarisation I
. O

We O
give O
a O
brief O
overview O
of O
ion B
channel I
disorders I
including O
malignant B
hyperthermia I
and O
their O
anaesthetic O
considerations O
. O

Increased O
serum O
soluble O
Fas O
in O
patients O
with O
acute B
liver I
failure I
due O
to O
paracetamol O
overdose B
. O

BACKGROUND O
/ O
AIMS O
: O
Experimental O
studies O
have O
suggested O
that O
apoptosis O
via O
the O
Fas O
/ O
Fas O
Ligand O
signaling O
system O
may O
play O
an O
important O
role O
in O
the O
development O
of O
acute B
liver I
failure I
. O

The O
aim O
of O
the O
study O
was O
to O
investigate O
the O
soluble O
form O
of O
Fas O
in O
patients O
with O
acute B
liver I
failure I
. O

METHODOLOGY O
: O
Serum O
levels O
of O
sFas O
( O
soluble O
Fas O
) O
were O
measured O
by O
ELISA O
in O
24 O
patients O
with O
acute B
liver I
failure I
and O
10 O
normal O
control O
subjects O
. O

RESULTS O
: O
Serum O
sFas O
was O
significantly O
increased O
in O
patients O
with O
acute B
liver I
failure I
( O
median O
, O
26 O
. O
8 O
U O
/ O
mL O
; O
range O
, O
6 O
. O
9 O
- O
52 O
. O
7 O
U O
/ O
mL O
) O
compared O
to O
the O
normal O
controls O
( O
median O
, O
8 O
. O
6 O
U O
/ O
mL O
; O
range O
, O
6 O
. O
5 O
- O
12 O
. O
0 O
U O
/ O
mL O
, O
P O
< O
0 O
. O
0001 O
) O
. O

Levels O
were O
significantly O
greater O
in O
patients O
with O
acute B
liver I
failure I
due O
to O
paracetamol O
overdose B
( O
median O
, O
28 O
. O
7 O
U O
/ O
mL O
; O
range O
, O
12 O
. O
8 O
- O
52 O
. O
7 O
U O
/ O
mL O
, O
n O
= O
17 O
) O
than O
those O
due O
to O
non O
- O
A O
to O
E O
hepatitis B
( O
median O
, O
12 O
. O
5 O
U O
/ O
mL O
; O
range O
, O
6 O
. O
9 O
- O
46 O
. O
0 O
U O
/ O
mL O
, O
n O
= O
7 O
, O
P O
< O
0 O
. O
01 O
) O
. O

CONCLUSIONS O
: O
The O
increased O
concentration O
of O
sFas O
in O
serum O
of O
patients O
with O
acute B
liver I
failure I
may O
reflect O
activation O
of O
Fas O
- O
mediated O
apoptosis O
in O
the O
liver O
and O
this O
together O
with O
increased O
tumor B
necrosis B
factor O
- O
alpha O
may O
be O
an O
important O
factor O
in O
liver O
cell O
loss O
. O

Acute B
renal I
failure I
occurring O
during O
intravenous O
desferrioxamine O
therapy O
: O
recovery O
after O
haemodialysis O
. O

From O
the O
results O
obtained O
, O
haemodialysis O
can O
therefore O
be O
suggested O
as O
a O
useful O
therapy O
in O
rare O
cases O
of O
progressive O
acute B
renal I
failure I
caused O
by O
desferrioxamine O
. O

OBJECTIVE O
: O
To O
report O
our O
clinical O
experience O
with O
abnormal B
ocular I
motility I
in O
patients O
treated O
with O
subtenon O
carboplatin O
chemotherapy O
. O

METHODS O
: O
We O
noted O
abnormal B
ocular I
motility I
in O
10 O
consecutive O
patients O
with O
retinoblastoma B
who O
had O
received O
subtenon O
carboplatin O
. O

The O
natural O
history O
of O
Vigabatrin O
associated O
visual B
field I
defects I
in O
patients O
electing O
to O
continue O
their O
medication O
. O

PURPOSE O
: O
To O
determine O
the O
natural O
history O
of O
visual B
field I
defects I
in O
a O
group O
of O
patients O
known O
to O
have O
Vigabatrin O
- O
associated O
changes O
who O
elected O
to O
continue O
the O
medication O
because O
of O
good O
seizure B
control O
. O

Following O
already O
published O
methodology O
( O
Eye O
2002 O
; O
16 O
; O
567 O
- O
571 O
) O
monocular O
mean O
radial O
degrees O
( O
MRDs O
) O
to O
the O
I O
/ O
4e O
isopter O
on O
Goldmann O
perimetry O
was O
calculated O
for O
the O
right O
eye O
at O
the O
time O
of O
discovery O
of O
a O
visual B
field I
defect I
and O
again O
after O
not O
less O
than O
18 O
months O
follow O
- O
up O
. O

CONCLUSION O
: O
Established O
visual B
field I
defects I
presumed O
to O
be O
due O
to O
Vigabatrin O
therapy O
did O
not O
usually O
progress O
in O
spite O
of O
continuing O
use O
of O
the O
medication O
. O

These O
data O
give O
support O
to O
the O
hypothesis O
that O
the O
pathogenesis O
of O
Vigabatrin O
- O
associated O
visual B
field I
defects I
may O
be O
an O
idiosyncratic O
adverse O
drug O
reaction O
rather O
than O
dose O
- O
dependent O
toxicity B
. O

Induction O
of O
rosaceiform O
dermatitis B
during O
treatment O
of O
facial B
inflammatory I
dermatoses I
with O
tacrolimus O
ointment O
. O

OBSERVATIONS O
: O
Six O
adult O
patients O
with O
inflammatory B
facial I
dermatoses I
were O
treated O
with O
tacrolimus O
ointment O
because O
of O
the O
ineffectiveness O
of O
standard O
treatments O
. O

Intravascular O
hemolysis B
and O
acute B
renal I
failure I
following O
intermittent O
rifampin O
therapy O
. O

Intravascular O
hemolysis B
leading O
to O
acute B
renal I
failure I
following O
rifampin O
therapy O
is O
extremely O
rare O
. O

Two O
patients O
with O
leprosy B
who O
developed O
hemolysis B
and O
acute B
renal I
failure I
following O
rifampin O
are O
reported O
. O

MRI O
- O
based O
maps O
suggest O
that O
chronic O
methamphetamine O
abuse O
causes O
a O
selective O
pattern O
of O
cerebral O
deterioration O
that O
contributes O
to O
impaired B
memory I
performance I
. O

The O
case O
discussed O
herein O
initially O
appeared O
to O
be O
neurogenic B
diabetes I
insipidus I
( O
DI B
) O
secondary O
to O
a O
traumatic B
brain I
injury I
. O

The O
case O
discussed O
herein O
initially O
appeared O
to O
be O
neurogenic B
diabetes I
insipidus I
( O
DI B
) O
secondary O
to O
a O
traumatic B
brain I
injury I
. O

BACKGROUND O
AND O
AIM O
: O
Interferon O
and O
ribavirin O
combination O
therapy O
for O
chronic B
hepatitis I
C I
produces O
hemolytic B
anemia I
. O

METHODS O
: O
Eighty O
- O
eight O
patients O
with O
chronic B
hepatitis I
C I
who O
received O
interferon O
- O
alpha O
- O
2b O
at O
a O
dose O
of O
6 O
MU O
administered O
intramuscularly O
for O
24 O
weeks O
in O
combination O
with O
ribavirin O
administered O
orally O
at O
a O
dose O
of O
600 O
mg O
or O
800 O
mg O
participated O
in O
the O
study O
. O

These O
results O
document O
for O
the O
first O
time O
in O
vivo O
that O
mitochondrial B
oxidative I
damage I
precedes O
nitrative O
damage O
. O

Acute B
renal I
insufficiency I
after O
high O
- O
dose O
melphalan O
in O
patients O
with O
primary B
systemic I
amyloidosis I
during O
stem O
cell O
transplantation O
. O

Acute B
renal I
insufficiency I
after O
high O
- O
dose O
melphalan O
in O
patients O
with O
primary B
systemic I
amyloidosis I
during O
stem O
cell O
transplantation O
. O

BACKGROUND O
: O
Patients O
with O
primary B
systemic I
amyloidosis I
( O
AL B
) O
have O
a O
poor O
prognosis O
. O

The O
authors O
have O
noted O
the O
development O
of O
acute B
renal I
insufficiency I
immediately O
after O
melphalan O
conditioning O
. O

Acute B
renal I
insufficiency I
( O
ARI B
) O
after O
high O
- O
dose O
melphalan O
was O
defined O
by O
a O
minimum O
increase O
of O
0 O
. O
5 O
mg O
/ O
dL O
( O
44 O
micromol O
/ O
L O
) O
in O
the O
serum O
creatinine O
level O
that O
is O
greater O
than O
50 O
% O
of O
baseline O
immediately O
after O
conditioning O
. O

After O
180 O
min O
of O
temporary O
middle B
cerebral I
artery I
occlusion I
in O
spontaneously O
hypertensive B
rats O
, O
the O
effect O
of O
phenylephrine O
- O
induced O
hypertension B
on O
ischemic B
brain I
injury I
and O
blood O
- O
brain O
barrier O
permeability O
was O
determined O
. O

Two O
cases O
of O
amisulpride O
overdose B
: O
a O
cause O
for O
prolonged B
QT I
syndrome I
. O

OBJECTIVES O
: O
To O
assess O
the O
effect O
of O
long O
- O
term O
HT O
on O
mortality O
, O
heart B
disease I
, O
venous B
thromboembolism I
, O
stroke B
, O
transient B
ischaemic I
attacks I
, O
breast B
cancer I
, O
colorectal B
cancer I
, O
ovarian B
cancer I
, O
endometrial B
cancer I
, O
gallbladder B
disease I
, O
cognitive O
function O
, O
dementia B
, O
fractures B
and O
quality O
of O
life O
. O

Factors O
associated O
with O
the O
development O
of O
fulminant B
hepatic I
failure I
were O
female O
sex O
( O
OR O
= O
25 O
; O
95 O
% O
CI O
: O
4 O
. O
1 O
- O
151 O
; O
P O
< O
. O
0001 O
) O
, O
hepatocellular O
damage O
( O
OR O
= O
7 O
. O
9 O
; O
95 O
% O
CI O
: O
1 O
. O
6 O
- O
37 O
; O
P O
< O
. O
009 O
) O
, O
and O
higher O
baseline O
plasma O
bilirubin O
value O
( O
OR O
= O
1 O
. O
15 O
; O
95 O
% O
CI O
: O
1 O
. O
09 O
- O
1 O
. O
22 O
; O
P O
< O
. O
0001 O
) O
. O

VCM O
administration O
to O
control O
rats O
significantly O
increased O
renal O
malondialdehyde O
( O
MDA O
) O
and O
urinary O
N O
- O
acetyl O
- O
beta O
- O
d O
- O
glucosaminidase O
( O
NAG O
, O
a O
marker O
of O
renal B
tubular I
injury I
) O
excretion O
but O
decreased O
superoxide O
dismutase O
( O
SOD O
) O
and O
catalase O
( O
CAT O
) O
activities O
. O

The O
specific O
aim O
of O
this O
retrospective O
, O
observational O
study O
was O
to O
assess O
safety O
and O
efficacy O
of O
long O
- O
term O
( O
21 O
months O
/ O
patient O
) O
, O
open O
- O
label O
, O
gemfibrozil O
- O
lovastatin O
treatment O
in O
80 O
patients O
with O
primary O
mixed O
hyperlipidemia B
( O
68 O
% O
of O
whom O
had O
atherosclerotic B
vascular I
disease I
) O
. O

Does O
domperidone O
potentiate O
mirtazapine O
- O
associated O
restless B
legs I
syndrome I
? O

There O
is O
now O
evidence O
to O
suggest O
a O
central O
role O
for O
the O
dopaminergic O
system O
in O
restless B
legs I
syndrome I
( O
RLS B
) O
. O

Antiandrogenic O
therapy O
can O
cause O
coronary B
arterial I
disease I
. O

After O
a O
period O
of O
2 O
. O
5 O
years O
on O
CPA O
treatment O
, O
four O
patients O
out O
of O
twenty O
- O
four O
were O
found O
to O
be O
affected O
by O
coronary B
heart I
disease I
. O

However O
, O
serious O
adverse O
effects O
, O
including O
torsade B
de I
pointes I
( O
Tdp B
) O
, O
have O
been O
reported O
. O

Drug O
- O
induced O
long B
QT I
syndrome I
in O
injection O
drug O
users O
receiving O
methadone O
: O
high O
frequency O
in O
hospitalized O
patients O
and O
risk O
factors O
. O

BACKGROUND O
: O
Drug O
- O
induced O
long B
QT I
syndrome I
is O
a O
serious O
adverse O
drug O
reaction O
. O

In O
the O
inpatient O
setting O
, O
the O
frequency O
of O
QT B
interval I
prolongation I
with O
methadone O
treatment O
, O
its O
dose O
dependence O
, O
and O
the O
importance O
of O
cofactors O
such O
as O
drug O
- O
drug O
interactions O
remain O
unknown O
. O

Six O
patients O
( O
3 O
. O
6 O
% O
) O
in O
the O
methadone O
group O
presented O
torsades B
de I
pointes I
. O

CONCLUSIONS O
: O
QT B
interval I
prolongation I
in O
methadone O
maintenance O
patients O
hospitalized O
in O
a O
tertiary O
care O
center O
is O
a O
frequent O
finding O
. O

Long B
QT I
syndrome I
can O
occur O
with O
low O
doses O
of O
methadone O
. O

Tonic O
dopaminergic O
stimulation O
impairs B
associative I
learning I
in O
healthy O
subjects O
. O

Acute B
renal I
failure I
associated O
with O
prolonged O
intake O
of O
slimming O
pills O
containing O
anthraquinones O
. O

We O
report O
a O
23 O
- O
year O
- O
old O
woman O
who O
developed O
acute B
renal I
failure I
following O
prolonged O
use O
of O
a O
proprietary O
Chinese O
herbal O
slimming O
pill O
that O
contained O
anthraquinone O
derivatives O
, O
extracted O
from O
Rhizoma O
Rhei O
( O
rhubarb O
) O
. O

The O
results O
provide O
new O
insight O
into O
the O
potential O
role O
of O
ectopic O
hilar O
granule O
cells O
in O
the O
pilocarpine O
model O
of O
temporal B
lobe I
epilepsy I
. O

Early O
paracentral O
visual B
field I
loss I
in O
patients O
taking O
hydroxychloroquine O
. O

Thirty O
- O
five O
patients O
( O
13 O
. O
4 O
% O
) O
had O
visual B
field I
abnormalities I
, O
which O
were O
attributed O
to O
hydroxychloroquine O
treatment O
in O
4 O
patients O
( O
1 O
. O
5 O
% O
) O
. O

CONCLUSIONS O
: O
The O
current O
study O
used O
a O
protocol O
of O
visual O
acuity O
and O
color O
vision O
assessment O
, O
funduscopy O
, O
and O
Humphrey O
10 O
- O
2 O
visual O
field O
testing O
and O
shows O
that O
visual B
field I
defects I
appeared O
before O
any O
corresponding O
changes O
in O
any O
other O
tested O
clinical O
parameters O
; O
the O
defects O
were O
reproducible O
and O
the O
test O
parameters O
were O
reliable O
. O

OBJECTIVES O
: O
The O
risk O
of O
acute B
myocardial I
infarction I
( O
AMI B
) O
with O
COX O
- O
2 O
inhibitors O
may O
offset O
their O
gastrointestinal O
( O
GI O
) O
benefit O
compared O
with O
non O
- O
selective O
( O
NS O
) O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
( O
NSAIDs O
) O
. O

It O
was O
reported O
that O
there O
was O
a O
case O
of O
severe B
malaria I
patient O
with O
jaundice B
who O
presented O
with O
arrhythmia B
( O
premature B
ventricular I
contraction I
) O
while O
getting O
quinine O
infusion O
was O
reported O
. O

On O
the O
second O
day O
the O
patient O
had O
vomitus B
, O
diarrhea B
, O
tinnitus B
, O
loss B
of I
hearing I
. O

After O
30 O
hours O
of O
quinine O
infusion O
the O
patient O
felt O
palpitation B
and O
electrocardiography O
( O
ECG O
) O
recording O
showed O
premature B
ventricular I
contraction I
( O
PVC B
) O
> O
5 O
x O
/ O
minute O
, O
trigemini O
, O
constant O
type O
- O
- O
sinoatrial B
block I
, O
positive O
U O
wave O
. O

We O
report O
a O
case O
of O
Wilson B
' I
s I
disease I
with O
chronic B
liver I
disease I
; O
moreover O
, O
in O
our O
patient O
, O
presenting O
also O
with O
high O
levels O
of O
state O
anxiety B
without O
depression B
, O
99mTc O
- O
ECD O
- O
SPECT O
showed O
cortical O
hypoperfusion O
in O
frontal O
lobes O
, O
more O
marked O
on O
the O
left O
frontal O
lobe O
. O

Acute B
encephalopathy I
and O
cerebral B
vasospasm I
after O
multiagent O
chemotherapy O
including O
PEG O
- O
asparaginase O
and O
intrathecal O
cytarabine O
for O
the O
treatment O
of O
acute B
lymphoblastic I
leukemia I
. O

A O
7 O
- O
year O
- O
old O
girl O
with O
an O
unusual O
reaction O
to O
induction O
chemotherapy O
for O
precursor O
B O
- O
cell O
acute B
lymphoblastic I
leukemia I
( O
ALL B
) O
is O
described O
. O

Mitral O
annuloplasty O
as O
a O
ventricular O
restoration O
method O
for O
the O
failing B
left I
ventricle I
: O
a O
pilot O
study O
. O

Brain O
magnetic O
resonance O
imaging O
did O
not O
demonstrate O
acute O
infarction B
and O
organic B
brain I
lesions I
. O

Frequency O
of O
transient O
ipsilateral O
vocal B
cord I
paralysis I
in O
patients O
undergoing O
carotid O
endarterectomy O
under O
local O
anesthesia O
. O

Temporary O
ipsilateral O
vocal B
nerve I
palsies I
due O
to O
local O
anesthetics O
have O
been O
described O
, O
however O
. O

Twelve O
patients O
( O
43 O
% O
) O
were O
found O
to O
have O
intraoperative O
ipsilateral O
vocal B
cord I
paralysis I
. O

There O
were O
no O
significant O
differences O
in O
operating O
time O
or O
volume O
or O
frequency O
of O
anesthetic O
administration O
in O
patients O
with O
temporary O
vocal B
cord I
paralysis I
compared O
with O
those O
without O
. O

CONCLUSION O
: O
Local O
anesthesia O
led O
to O
temporary O
ipsilateral O
vocal B
cord I
paralysis I
in O
almost O
half O
of O
these O
patients O
. O

In O
patients O
with O
preoperative O
contralateral O
vocal B
cord I
paralysis I
, O
surgery O
under O
general O
anesthesia O
should O
be O
considered O
. O

Impaired B
fear I
recognition I
in O
regular O
recreational O
cocaine O
users O
. O

RESULTS O
: O
There O
were O
no O
group O
differences O
in O
psychopathology O
or O
" O
eyes O
task O
" O
performance O
, O
but O
the O
RC O
group O
, O
who O
otherwise O
had O
similar O
illicit O
substance O
use O
histories O
to O
the O
OC O
group O
, O
exhibited O
impaired B
fear I
recognition I
accuracy O
compared O
to O
the O
OC O
and O
CN O
groups O
. O

Possible O
parallels O
between O
RC O
users O
and O
psychopaths B
with O
respect O
to O
impaired B
fear I
recognition I
, O
amygdala B
dysfunction I
, O
and O
etiology O
are O
discussed O
. O

Additionally O
, O
in O
models O
of O
prolonged B
status I
epilepticus I
the O
pars O
reticulata O
of O
substantia O
nigra O
( O
SNR O
) O
suffers O
from O
a O
massive O
lesion O
which O
may O
arise O
from O
a O
massive O
metabolic B
derangement I
and O
hyperexcitation O
developing O
in O
the O
activated O
SNR O
. O

In O
a O
further O
group O
of O
animals O
surviving O
1 O
to O
5 O
days O
, O
conventional O
paraffin O
- O
sections O
confirmed O
the O
neuronal O
and O
glial O
damage B
of I
SNR I
. O

Acute B
tubulo I
- I
interstitial I
nephritis I
( O
ATIN B
) O
is O
an O
important O
cause O
of O
acute B
renal I
failure I
resulting O
from O
a O
variety O
of O
insults O
, O
including O
immune O
complex O
- O
mediated O
tubulo B
- I
interstitial I
injury I
, O
but O
drugs O
such O
as O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
( O
NSAIDs O
) O
are O
a O
far O
more O
frequent O
cause O
. O

We O
report O
on O
a O
14 O
- O
year O
- O
old O
boy O
who O
developed O
acute B
renal I
failure I
2 O
weeks O
after O
aortic O
valve O
surgery O
. O

We O
describe O
a O
case O
of O
a O
patient O
with O
Staphylococcal B
IE I
who O
developed O
acute B
renal I
failure I
secondary O
to O
a O
segmental O
necrotising O
glomerulonephritis B
while O
being O
treated O
with O
rifampicin O
, O
and O
review O
the O
literature O
regarding O
this O
complication O
of O
rifampicin O
therapy O
. O

BACKGROUND O
: O
Lamivudine O
is O
used O
for O
the O
treatment O
of O
chronic B
hepatitis I
B I
patients O
. O

Recent O
studies O
show O
that O
the O
YMDD O
motif O
mutants O
( O
resistant O
hepatitis B
B I
virus O
) O
occur O
as O
natural O
genome O
variability O
in O
lamivudine O
- O
untreated O
chronic B
hepatitis I
B I
patients O
. O

In O
this O
study O
we O
aimed O
to O
determine O
the O
rate O
of O
YMDD O
motif O
mutants O
in O
lamivudine O
- O
untreated O
chronic B
hepatitis I
B I
patients O
in O
Iran O
. O

PATIENTS O
AND O
METHODS O
: O
A O
total O
of O
77 O
chronic B
hepatitis I
B I
patients O
who O
had O
not O
been O
treated O
with O
lamivudine O
were O
included O
in O
the O
study O
. O

CONCLUSION O
: O
Although O
the O
natural O
occurrence O
of O
YMDD O
motif O
mutants O
in O
lamivudine O
- O
untreated O
patients O
with O
chronic B
hepatitis I
B I
has O
been O
reported O
, O
these O
mutants O
were O
not O
detected O
in O
Iranian O
lamivudine O
- O
untreated O
chronic B
hepatitis I
B I
patients O
. O

CONCLUSION O
: O
Although O
the O
natural O
occurrence O
of O
YMDD O
motif O
mutants O
in O
lamivudine O
- O
untreated O
patients O
with O
chronic B
hepatitis I
B I
has O
been O
reported O
, O
these O
mutants O
were O
not O
detected O
in O
Iranian O
lamivudine O
- O
untreated O
chronic B
hepatitis I
B I
patients O
. O

Branch O
retinal B
vein I
occlusion I
and O
fluoxetine O
. O

A O
case O
of O
branch O
retinal B
vein I
occlusion I
associated O
with O
fluoxetine O
- O
induced O
secondary O
hypertension B
is O
described O
. O

Previous O
studies O
have O
examined O
the O
expression O
and O
regulation O
of O
tyrosine O
kinase O
receptors O
( O
Trks O
) O
in O
micturition O
reflexes O
with O
urinary B
bladder I
inflammation I
. O

Spectrum O
of O
adverse O
events O
after O
generic O
HAART O
in O
southern O
Indian O
HIV B
- I
infected I
patients O
. O

To O
determine O
the O
incidence O
of O
clinically O
significant O
adverse O
events O
after O
long O
- O
term O
, O
fixed O
- O
dose O
, O
generic O
highly O
active O
antiretroviral O
therapy O
( O
HAART O
) O
use O
among O
HIV B
- I
infected I
individuals O
in O
South O
India O
, O
we O
examined O
the O
experiences O
of O
3154 O
HIV B
- I
infected I
individuals O
who O
received O
a O
minimum O
of O
3 O
months O
of O
generic O
HAART O
between O
February O
1996 O
and O
December O
2006 O
at O
a O
tertiary O
HIV O
care O
referral O
center O
in O
South O
India O
. O

To O
determine O
the O
incidence O
of O
clinically O
significant O
adverse O
events O
after O
long O
- O
term O
, O
fixed O
- O
dose O
, O
generic O
highly O
active O
antiretroviral O
therapy O
( O
HAART O
) O
use O
among O
HIV B
- I
infected I
individuals O
in O
South O
India O
, O
we O
examined O
the O
experiences O
of O
3154 O
HIV B
- I
infected I
individuals O
who O
received O
a O
minimum O
of O
3 O
months O
of O
generic O
HAART O
between O
February O
1996 O
and O
December O
2006 O
at O
a O
tertiary O
HIV O
care O
referral O
center O
in O
South O
India O
. O

Women O
were O
significantly O
more O
likely O
to O
experience O
lactic B
acidosis I
, O
while O
men O
were O
significantly O
more O
likely O
to O
experience O
immune B
reconstitution I
syndrome I
( O
p O
< O
0 O
. O
05 O
) O
. O

BACKGROUND O
: O
Recent O
studies O
confirmed O
a O
high O
incidence O
of O
sensory B
axonal I
neuropathy I
in O
patients O
treated O
with O
different O
doses O
of O
thalidomide O
. O

The O
study O
' O
s O
aims O
were O
to O
measure O
variations O
in O
sural O
nerve O
sensory O
action O
potential O
( O
SAP O
) O
amplitude O
in O
patients O
with O
refractory O
cutaneous B
lupus I
erythematosus I
( O
CLE B
) O
treated O
with O
thalidomide O
and O
use O
these O
findings O
to O
identify O
the O
neurotoxic B
potential O
of O
thalidomide O
and O
the O
recovery O
capacity O
of O
sensory O
fibres O
after O
discontinuation O
of O
treatment O
. O

Amiodarone O
- O
related O
pulmonary B
mass I
and O
unique O
membranous B
glomerulonephritis I
in O
a O
patient O
with O
valvular B
heart I
disease I
: O
Diagnostic O
pitfall O
and O
new O
findings O
. O

Reported O
herein O
is O
an O
autopsy O
case O
of O
valvular B
heart I
disease I
, O
in O
a O
patient O
who O
developed O
a O
lung B
mass I
( O
1 O
. O
5 O
cm O
in O
diameter O
) O
and O
proteinuria B
( O
2 O
. O
76 O
g O
/ O
day O
) O
after O
treatment O
with O
amiodarone O
for O
a O
long O
time O
. O

Risk O
of O
coronary B
artery I
disease I
associated O
with O
initial O
sulphonylurea O
treatment O
of O
patients O
with O
type B
2 I
diabetes I
: O
a O
matched O
case O
- O
control O
study O
. O

Risk O
of O
coronary B
artery I
disease I
associated O
with O
initial O
sulphonylurea O
treatment O
of O
patients O
with O
type B
2 I
diabetes I
: O
a O
matched O
case O
- O
control O
study O
. O

AIMS O
: O
This O
study O
sought O
to O
assess O
the O
risk O
of O
developing O
coronary B
artery I
disease I
( O
CAD B
) O
associated O
with O
initial O
treatment O
of O
type B
2 I
diabetes I
with O
different O
sulphonylureas O
. O

AIMS O
: O
This O
study O
sought O
to O
assess O
the O
risk O
of O
developing O
coronary B
artery I
disease I
( O
CAD B
) O
associated O
with O
initial O
treatment O
of O
type B
2 I
diabetes I
with O
different O
sulphonylureas O
. O

METHODS O
: O
In O
type B
2 I
diabetic I
patients O
, O
cases O
who O
developed O
CAD B
were O
compared O
retrospectively O
with O
controls O
that O
did O
not O
. O

CONCLUSIONS O
: O
Initiating O
treatment O
of O
type B
2 I
diabetes I
with O
glibenclamide O
or O
glipizide O
is O
associated O
with O
increased O
risk O
of O
CAD B
in O
comparison O
to O
gliclazide O
or O
glimepiride O
. O

Prolonged O
treatment O
with O
losartan O
showed O
further O
reduction O
of O
glomerulosclerosis B
associated O
with O
reduced O
progression O
of O
tubular O
atrophy B
and O
interstitial B
fibrosis I
, O
thus O
preventing O
heavy O
proteinuria B
and O
chronic B
renal I
failure I
. O

CONCLUSION O
: O
Losartan O
reduces O
the O
rate O
of O
progression O
of O
ADR O
- O
induced O
focal B
segmental I
glomerulosclerosis I
to O
end B
- I
stage I
renal I
disease I
in O
SHR O
. O

Carbimazole O
induced O
ANCA B
positive I
vasculitis I
. O

We O
report O
a O
patient O
with O
Graves B
' I
disease I
who O
developed O
ANCA O
positive O
carbimazole O
induced O
vasculitis B
. O

BACKGROUND O
: O
Coronary B
heart I
disease I
and O
cerebrovascular B
disease I
are O
leading O
causes O
of O
death O
in O
the O
United O
States O
. O

Preventive O
Services O
Task O
Force O
( O
USPSTF O
) O
strongly O
recommended O
that O
clinicians O
discuss O
aspirin O
with O
adults O
who O
are O
at O
increased O
risk O
for O
coronary B
heart I
disease I
. O

In O
the O
ICU O
, O
we O
found O
rhabdomyolysis B
, O
acute B
renal I
failure I
and O
acute O
respiratory B
failure I
. O

After O
MRI O
, O
we O
found O
cerebral B
ischemic I
infarction I
. O

Liver O
transplantation O
for O
acutely O
ill O
patients O
with O
fulminant B
liver I
failure I
carries O
high O
intraoperative O
and O
immediate O
postoperative O
risks O
. O

These O
are O
increased O
with O
the O
presence O
of O
concomitant O
acute B
kidney I
injury I
( O
AKI B
) O
and O
intraoperative O
dialysis O
is O
sometimes O
required O
to O
allow O
the O
transplant O
to O
proceed O
. O

The O
derangements O
in O
the O
procoagulant O
and O
anticoagulant O
pathways O
during O
fulminant B
liver I
failure I
can O
lead O
to O
difficulties O
with O
anticoagulation O
during O
dialysis O
, O
especially O
when O
continued O
in O
the O
operating O
room O
. O

We O
report O
a O
case O
of O
a O
40 O
- O
year O
- O
old O
female O
with O
acetaminophen O
- O
induced O
fulminant B
liver I
failure I
with O
associated O
AKI B
who O
underwent O
intraoperative O
dialytic O
support O
during O
liver O
transplantation O
anticoagulated O
with O
citrate O
dialysate O
during O
the O
entire O
procedure O
. O

Citrate O
dialysate O
is O
a O
safe O
alternative O
for O
intradialytic O
support O
of O
liver O
transplantation O
in O
fulminant B
liver I
failure I
. O

BACKGROUND O
: O
Most O
patients O
presenting O
to O
emergency O
departments O
( O
EDs O
) O
with O
cocaine O
- O
associated O
chest B
pain I
are O
admitted O
for O
at O
least O
12 O
hours O
and O
receive O
a O
" O
rule O
out O
acute B
coronary I
syndrome I
" O
protocol O
, O
often O
with O
noninvasive O
testing O
prior O
to O
discharge O
. O

Drug O
- O
related O
globus B
pallidus I
infarctions I
are O
most O
often O
associated O
with O
heroin O
. O

Bilateral O
basal B
ganglia I
infarcts I
after O
the O
use O
of O
cocaine O
, O
without O
concurrent O
heroin O
use O
, O
have O
never O
been O
reported O
. O

Prolonged O
hypothermia B
as O
a O
bridge O
to O
recovery O
for O
cerebral B
edema I
and O
intracranial B
hypertension I
associated O
with O
fulminant B
hepatic I
failure I
. O

BACKGROUND O
: O
To O
review O
evidence O
- O
based O
treatment O
options O
in O
patients O
with O
cerebral B
edema I
complicating O
fulminant B
hepatic I
failure I
( O
FHF B
) O
and O
discuss O
the O
potential O
applications O
of O
hypothermia B
. O

Acute B
renal I
failure I
after O
high O
- O
dose O
methotrexate O
therapy O
in O
a O
patient O
with O
ileostomy O
. O

We O
report O
a O
case O
of O
acute B
renal I
failure I
after O
HD O
- O
MTX O
therapy O
in O
a O
patient O
with O
ileostomy O
, O
The O
patient O
was O
a O
3 O
- O
year O
- O
old O
boy O
who O
had O
received O
a O
living O
- O
related O
liver O
transplantation O
for O
congenital O
biliary B
atresia I
. O

Subsequent O
HD O
- O
MTX O
therapy O
caused O
acute B
renal I
failure I
that O
required O
continuous O
hemodialysis O
. O

We O
supposed O
that O
intravascular O
hypovolemia B
due O
to O
substantial O
drainage O
from O
the O
ileostoma O
caused O
acute B
prerenal I
failure I
. O

Medical O
and O
psychiatric O
outcomes O
for O
patients O
transplanted O
for O
acetaminophen O
- O
induced O
acute B
liver I
failure I
: O
a O
case O
- O
control O
study O
. O

BACKGROUND O
: O
Acetaminophen O
- O
induced O
hepatotoxicity B
is O
the O
most O
common O
cause O
of O
acute B
liver I
failure I
( O
ALF B
) O
in O
the O
UK O
. O

AIMS O
AND O
METHODS O
: O
We O
compared O
the O
severity O
of O
pretransplant O
illness O
, O
psychiatric O
co O
- O
morbidity O
, O
medical O
and O
psychosocial O
outcomes O
of O
all O
patients O
who O
had O
undergone O
liver O
transplantation O
( O
LT O
) O
emergently O
between O
1999 O
- O
2004 O
for O
acetaminophen O
- O
induced O
ALF B
( O
n O
= O
36 O
) O
with O
age O
- O
and O
sex O
- O
matched O
patients O
undergoing O
emergent O
LT O
for O
non O
- O
acetaminophen O
- O
induced O
ALF B
( O
n O
= O
35 O
) O
and O
elective O
LT O
for O
chronic B
liver I
disease I
( O
CLD B
, O
n O
= O
34 O
) O
. O

Insights O
could O
be O
gained O
by O
pooling O
data O
on O
MB B
frequency O
stratified O
by O
antithrombotic O
use O
in O
cohorts O
with O
ICH B
and O
ischemic B
stroke I
( O
IS B
) O
/ O
transient B
ischemic I
attack I
( O
TIA B
) O
. O

Abductor O
paralysis B
after O
botox O
injection O
for O
adductor B
spasmodic I
dysphonia I
. O

OBJECTIVES O
/ O
HYPOTHESIS O
: O
Botulinum O
toxin O
( O
Botox O
) O
injections O
into O
the O
thyroarytenoid O
muscles O
are O
the O
current O
standard O
of O
care O
for O
adductor B
spasmodic I
dysphonia I
( O
ADSD B
) O
. O

We O
hypothesized O
that O
cocaine B
abuse I
may O
lead O
to O
altered O
mitochondrial O
function O
that O
in O
turn O
may O
cause O
left B
ventricular I
dysfunction I
. O

OBJECTIVE O
: O
A O
multicenter O
, O
controlled O
trial O
showed O
that O
early O
blockade O
of O
the O
renin O
- O
angiotensin O
system O
in O
patients O
with O
type B
1 I
diabetes I
and O
normoalbuminuria O
did O
not O
retard O
the O
progression O
of O
nephropathy B
, O
suggesting O
that O
other O
mechanism O
( O
s O
) O
are O
involved O
in O
the O
pathogenesis O
of O
early O
diabetic B
nephropathy I
( O
diabetic B
nephropathy I
) O
. O

Cytostatic O
and O
anti O
- O
angiogenic O
effects O
of O
temsirolimus O
in O
refractory O
mantle B
cell I
lymphoma I
. O

Mantle B
cell I
lymphoma I
( O
MCL B
) O
is O
a O
rare O
and O
aggressive O
type O
of O
B B
- I
cell I
non I
- I
Hodgkin I
' I
s I
lymphoma I
. O

Acute B
renal I
failure I
due O
to O
rifampicin O
. O

A O
76 O
year O
- O
old O
woman O
with O
a O
history O
of O
coronary O
artery O
bypass O
grafting O
and O
prior O
myocardial B
infarction I
was O
transferred O
to O
the O
emergency O
room O
with O
loss B
of I
consciousness I
due O
to O
marked O
bradycardia B
caused O
by O
hyperkalemia B
. O

On O
day O
8 O
, O
the O
patient O
developed O
acute B
renal I
failure I
( O
serum O
creatinine O
1 O
. O
9 O
mg O
/ O
dL O
, O
increased O
from O
1 O
. O
2 O
mg O
/ O
dL O
the O
previous O
day O
and O
0 O
. O
8 O
mg O
/ O
dL O
on O
admission O
) O
. O

Late O
- O
onset O
scleroderma B
renal I
crisis I
induced O
by O
tacrolimus O
and O
prednisolone O
: O
a O
case O
report O
. O

Scleroderma B
renal I
crisis I
( O
SRC B
) O
is O
a O
rare O
complication O
of O
systemic B
sclerosis I
( O
SSc B
) O
but O
can O
be O
severe O
enough O
to O
require O
temporary O
or O
permanent O
renal O
replacement O
therapy O
. O

Methyldopa O
causes O
an O
autoimmune B
hemolytic I
anemia I
in O
a O
small O
percentage O
of O
patients O
who O
take O
the O
drug O
. O

Co O
- O
morbid O
major O
depressive B
disorder I
( O
OR O
= O
7 O
. O
18 O
, O
95 O
CI O
= O
2 O
. O
612 O
- O
19 O
. O
708 O
) O
, O
bipolar B
disorder I
( O
OR O
= O
13 O
. O
807 O
, O
95 O
CI O
= O
5 O
. O
194 O
- O
36 O
. O
706 O
) O
, O
antisocial B
personality I
disorder I
( O
OR O
= O
12 O
. O
619 O
, O
95 O
CI O
= O
6 O
. O
702 O
- O
23 O
. O
759 O
) O
and O
heavy O
methamphetamine O
uses O
were O
significantly O
associated O
with O
lifetime O
methamphetamine O
- O
induced O
psychosis B
after O
adjusted O
for O
other O
factors O
. O

Major B
depressive I
disorder I
( O
OR O
= O
2 O
. O
870 O
, O
CI O
= O
1 O
. O
154 O
- O
7 O
. O
142 O
) O
and O
antisocial B
personality I
disorder I
( O
OR O
= O
3 O
. O
299 O
, O
95 O
CI O
= O
1 O
. O
375 O
- O
7 O
. O
914 O
) O
were O
the O
only O
factors O
associated O
with O
current O
psychosis B
. O

Major B
depressive I
disorder I
( O
OR O
= O
2 O
. O
870 O
, O
CI O
= O
1 O
. O
154 O
- O
7 O
. O
142 O
) O
and O
antisocial B
personality I
disorder I
( O
OR O
= O
3 O
. O
299 O
, O
95 O
CI O
= O
1 O
. O
375 O
- O
7 O
. O
914 O
) O
were O
the O
only O
factors O
associated O
with O
current O
psychosis B
. O

These O
results O
suggest O
that O
alterations O
in O
cerebellar O
sensory O
processing O
function O
, O
occurring O
secondary O
to O
abnormal O
basal O
ganglia O
signals O
reaching O
it O
, O
may O
be O
an O
important O
element O
contributing O
to O
the O
maladaptive O
sensorimotor O
plasticity O
of O
M1 O
and O
the O
emergence O
of O
abnormal B
involuntary I
movements I
. O

Peripheral B
neuropathy I
was O
observed O
only O
in O
2 O
. O
5 O
% O
of O
patients O
and O
deep B
vein I
thrombosis I
in O
5 O
. O
7 O
% O
. O

Reports O
that O
satisfy O
defined O
criteria O
were O
classified O
as O
acute B
kidney I
injury I
, O
kidney B
tubular I
dysfunction I
and O
Fanconi B
syndrome I
. O

Reports O
that O
satisfy O
defined O
criteria O
were O
classified O
as O
acute B
kidney I
injury I
, O
kidney B
tubular I
dysfunction I
and O
Fanconi B
syndrome I
. O

Of O
the O
407 O
Yellow O
Card O
records O
analysed O
, O
106 O
satisfied O
criteria O
for O
TDF O
- O
related O
kidney B
disease I
, O
of O
which O
53 O
( O
50 O
% O
) O
had O
features O
of O
kidney B
tubular I
dysfunction I
, O
35 O
( O
33 O
% O
) O
were O
found O
to O
have O
features O
of O
glomerular B
dysfunction I
and O
18 O
( O
17 O
% O
) O
had O
Fanconi B
syndrome I
. O

We O
describe O
a O
case O
of O
progressive O
loss B
of I
vision I
associated O
with O
linezolid O
therapy O
. O

A O
45 O
- O
year O
- O
old O
male O
patient O
who O
was O
on O
treatment O
with O
multiple O
second O
- O
line O
anti O
- O
tuberculous O
drugs O
including O
linezolid O
and O
ethambutol O
for O
extensively B
drug I
- I
resistant I
tuberculosis I
( O
XDR B
- I
TB I
) O
presented O
to O
us O
with O
painless O
progressive O
loss B
of I
vision I
in O
both O
eyes O
. O

A O
45 O
- O
year O
- O
old O
male O
patient O
who O
was O
on O
treatment O
with O
multiple O
second O
- O
line O
anti O
- O
tuberculous O
drugs O
including O
linezolid O
and O
ethambutol O
for O
extensively B
drug I
- I
resistant I
tuberculosis I
( O
XDR B
- I
TB I
) O
presented O
to O
us O
with O
painless O
progressive O
loss B
of I
vision I
in O
both O
eyes O
. O

Color O
vision O
was O
defective O
and O
fundus O
examination O
revealed O
optic B
disc I
edema I
in O
both O
eyes O
. O

Ethambutol O
- O
induced O
toxic B
optic I
neuropathy I
was O
suspected O
and O
tablet O
ethambutol O
was O
withdrawn O
. O

Deterioration B
of I
vision I
occurred O
despite O
withdrawal O
of O
ethambutol O
. O

Incidence O
of O
heparin O
- O
induced O
thrombocytopenia B
type I
II I
and O
postoperative O
recovery O
of O
platelet O
count O
in O
liver O
graft O
recipients O
: O
a O
retrospective O
cohort O
analysis O
. O

The O
impact O
of O
immune O
- O
mediated O
heparin O
- O
induced O
thrombocytopenia B
type I
II I
( O
HIT B
type I
II I
) O
as O
a O
cause O
of O
thrombocytopenia B
after O
liver O
transplantation O
is O
not O
yet O
understood O
, O
with O
few O
literature O
citations O
reporting O
contradictory O
results O
. O

The O
impact O
of O
immune O
- O
mediated O
heparin O
- O
induced O
thrombocytopenia B
type I
II I
( O
HIT B
type I
II I
) O
as O
a O
cause O
of O
thrombocytopenia B
after O
liver O
transplantation O
is O
not O
yet O
understood O
, O
with O
few O
literature O
citations O
reporting O
contradictory O
results O
. O

The O
aim O
of O
our O
study O
was O
to O
demonstrate O
the O
perioperative O
course O
of O
thrombocytopenia B
after O
liver O
transplantation O
and O
determine O
the O
occurrence O
of O
clinical O
HIT B
type I
II I
. O

Preoperative O
platelet O
count O
, O
postoperative O
course O
of O
platelets O
, O
and O
clinical O
signs O
of O
HIT B
type I
II I
were O
analyzed O
. O

Regarding O
HIT B
II I
, O
there O
were O
four O
( O
1 O
. O
95 O
% O
) O
patients O
with O
a O
background O
of O
HIT B
type I
II I
. O

For O
further O
reduction O
of O
HIT B
type I
II I
, O
the O
use O
of O
intravenous O
heparin O
should O
be O
avoided O
and O
the O
prophylactic O
anticoagulation O
should O
be O
performed O
with O
low O
- O
molecular O
- O
weight O
heparin O
after O
normalization O
of O
platelet O
count O
. O

Takotsubo B
syndrome I
( O
or O
apical B
ballooning I
syndrome I
) O
secondary O
to O
Zolmitriptan O
. O

Takotsubo B
syndrome I
( O
TS B
) O
, O
also O
known O
as O
broken B
heart I
syndrome I
, O
is O
characterized O
by O
left O
ventricle O
apical O
ballooning O
with O
elevated O
cardiac O
biomarkers O
and O
electrocardiographic O
changes O
suggestive O
of O
an O
acute B
coronary I
syndrome I
( O
ie O
, O
ST O
- O
segment O
elevation O
, O
T O
wave O
inversions O
, O
and O
pathologic O
Q O
waves O
) O
. O

Takotsubo B
syndrome I
( O
TS B
) O
, O
also O
known O
as O
broken B
heart I
syndrome I
, O
is O
characterized O
by O
left O
ventricle O
apical O
ballooning O
with O
elevated O
cardiac O
biomarkers O
and O
electrocardiographic O
changes O
suggestive O
of O
an O
acute B
coronary I
syndrome I
( O
ie O
, O
ST O
- O
segment O
elevation O
, O
T O
wave O
inversions O
, O
and O
pathologic O
Q O
waves O
) O
. O

We O
report O
a O
case O
of O
54 O
- O
year O
- O
old O
woman O
with O
medical O
history O
of O
mitral B
valve I
prolapse I
and O
migraines B
, O
who O
was O
admitted O
to O
the O
hospital O
for O
substernal O
chest B
pain I
and O
electrocardiogram O
demonstrated O
1 O
/ O
2 O
mm O
ST O
- O
segment O
elevation O
in O
leads O
II O
, O
III O
, O
aVF O
, O
V5 O
, O
and O
V6 O
and O
positive O
troponin O
I O
. O

Extensive O
literature O
search O
revealed O
multiple O
cases O
of O
coronary B
artery I
vasospasm I
secondary O
to O
zolmitriptan O
, O
but O
none O
of O
the O
cases O
were O
associated O
with O
TS B
. O

Patients O
with O
risk O
factors O
for O
acute B
renal I
failure I
were O
excluded O
. O

Among O
a O
total O
of O
60 O
patients O
included O
in O
the O
study O
, O
16 O
patients O
developed O
acute B
renal I
failure I
( O
ARF B
) O
on O
the O
second O
day O
after O
contrast O
material O
was O
injected O
( O
26 O
. O
6 O
% O
) O
. O

Neurocognitive O
and O
neuroradiologic O
central O
nervous O
system O
late O
effects O
in O
children O
treated O
on O
Pediatric O
Oncology O
Group O
( O
POG O
) O
P9605 O
( O
standard O
risk O
) O
and O
P9201 O
( O
lesser O
risk O
) O
acute B
lymphoblastic I
leukemia I
protocols O
( O
ACCL0131 O
) O
: O
a O
methotrexate O
consequence O
? O

Concerns O
about O
long O
- O
term O
methotrexate O
( O
MTX O
) O
neurotoxicity B
in O
the O
1990s O
led O
to O
modifications O
in O
intrathecal O
( O
IT O
) O
therapy O
, O
leucovorin O
rescue O
, O
and O
frequency O
of O
systemic O
MTX O
administration O
in O
children O
with O
acute B
lymphoblastic I
leukemia I
. O

A O
total O
of O
66 O
children O
from O
16 O
Pediatric O
Oncology O
Group O
institutions O
with O
" O
standard O
- O
risk O
" O
acute B
lymphoblastic I
leukemia I
, O
1 O
. O
00 O
to O
9 O
. O
99 O
years O
at O
diagnosis O
, O
without O
evidence O
of O
CNS O
leukemia B
at O
diagnosis O
were O
enrolled O
on O
ACCL0131 O
: O
28 O
from O
P9201 O
and O
38 O
from O
P9605 O
. O

We O
report O
a O
45 O
- O
year O
- O
old O
lady O
with O
chronic B
kidney I
disease I
stage O
4 O
due O
to O
chronic O
tubulointerstial B
disease I
. O

Two O
hours O
after O
the O
sixth O
dose O
of O
TNA O
, O
she O
had O
an O
episode O
of O
generalized O
tonic B
clonic I
convulsions I
. O

Investigations O
of O
the O
patient O
revealed O
no O
biochemical O
or O
structural O
central O
nervous B
system I
abnormalities I
that O
could O
have O
provoked O
the O
convulsions B
. O

In O
particular O
the O
temporal O
relationship O
of O
bone B
marrow I
suppression I
to O
the O
initiation O
of O
fluconazole O
and O
the O
abatement O
of O
symptoms O
that O
rapidly O
reversed O
immediately O
following O
discontinuation O
. O

Poisoning B
with O
yellow O
phosphorus O
classically O
manifests O
with O
acute B
hepatitis I
leading O
to O
acute B
liver I
failure I
which O
may O
need O
liver O
transplantation O
. O

This O
patient O
had O
no O
associated O
personality B
disorder I
( O
particularly O
no O
antisocial B
disorder I
) O
and O
no O
substance B
abuse I
disorder I
. O

Independent O
predictors O
of O
postoperative O
seizures B
included O
age O
, O
female O
sex O
, O
redo O
cardiac O
surgery O
, O
calcification O
of O
ascending O
aorta O
, O
congestive B
heart I
failure I
, O
deep O
hypothermic B
circulatory O
arrest O
, O
duration O
of O
aortic O
cross O
- O
clamp O
and O
tranexamic O
acid O
. O

Dysfunctional B
overnight I
memory I
consolidation O
in O
ecstasy O
users O
. O

Ecstasy O
users O
demonstrated O
impaired B
overnight I
memory I
consolidation O
, O
a O
finding O
that O
was O
more O
pronounced O
following O
associative O
interference O
. O

A O
Case O
of O
Sudden B
Cardiac I
Death I
due O
to O
Pilsicainide O
- O
Induced O
Torsades B
de I
Pointes I
. O

A O
Case O
of O
Sudden B
Cardiac I
Death I
due O
to O
Pilsicainide O
- O
Induced O
Torsades B
de I
Pointes I
. O

An O
84 O
- O
year O
- O
old O
male O
received O
oral O
pilsicainide O
, O
a O
pure O
sodium O
channel O
blocker O
with O
slow O
recovery O
kinetics O
, O
to O
convert O
his O
paroxysmal O
atrial B
fibrillation I
to O
a O
sinus O
rhythm O
; O
the O
patient O
developed O
sudden B
cardiac I
death I
two O
days O
later O
. O

The O
Holter O
electrocardiogram O
, O
which O
was O
worn O
by O
chance O
, O
revealed O
torsade B
de I
pointes I
with O
gradually O
prolonged O
QT O
intervals O
. O

Although O
the O
patient O
' O
s O
renal O
function O
was O
not O
highly O
impaired O
and O
the O
dose O
of O
pilsicainide O
was O
low O
, O
the O
plasma O
concentration O
of O
pilsicainide O
may O
have O
been O
high O
, O
which O
can O
produce O
torsades B
de I
pointes I
in O
the O
octogenarian O
. O

All O
- O
trans O
retinoic O
acid O
- O
induced O
inflammatory O
myositis B
in O
a O
patient O
with O
acute B
promyelocytic I
leukemia I
. O

All O
- O
trans O
retinoic O
acid O
( O
ATRA O
) O
, O
a O
component O
of O
standard O
therapy O
for O
acute B
promyelocytic I
leukemia I
( O
APL B
) O
, O
is O
associated O
with O
potentially O
serious O
but O
treatable O
adverse O
effects O
involving O
numerous O
organ O
systems O
, O
including O
rare O
skeletal O
muscle O
involvement O
. O

At O
the O
time O
of O
treatment O
, O
she O
was O
on O
continuous O
renal O
replacement O
therapy O
due O
to O
sequelae O
of O
tumor B
lysis I
syndrome I
( O
TLS B
) O
. O

Finally O
, O
the O
IKr O
blockers O
, O
Terfenadine O
and O
Citalopram O
, O
which O
are O
reported O
to O
cause O
Torsade B
de I
Pointes I
( O
TdP B
) O
in O
clinical O
practice O
, O
produced O
early O
afterdepolarization O
( O
EAD O
) O
. O

BACKGROUND O
: O
S O
- O
53482 O
and O
S O
- O
23121 O
are O
N O
- O
phenylimide O
herbicides O
and O
produced O
embryolethality B
, O
teratogenicity B
( O
mainly O
ventricular B
septal I
defects I
and O
wavy O
ribs O
) O
, O
and O
growth B
retardation I
in O
rats O
in O
conventional O
oral O
developmental O
toxicity B
studies O
. O

Dermal O
administration O
of O
S O
- O
23121 O
at O
800 O
mg O
/ O
kg O
resulted O
in O
an O
increased O
incidence O
of O
embryonic B
death I
and O
ventricular B
septal I
defect I
, O
but O
retarded O
fetal O
growth O
was O
not O
observed O
as O
it O
was O
following O
oral O
exposure O
to O
S O
- O
23121 O
. O

The O
primary O
outcome O
was O
acute B
kidney I
injury I
( O
AKI B
) O
. O

Chronic O
treatment O
with O
metformin O
suppresses O
toll O
- O
like O
receptor O
4 O
signaling O
and O
attenuates O
left B
ventricular I
dysfunction I
following O
myocardial B
infarction I
. O

Isoproterenol O
( O
100mg O
/ O
kg O
) O
was O
injected O
subcutaneously O
on O
the O
13th O
and O
14th O
days O
to O
induce O
acute B
myocardial I
infarction I
. O

The O
left B
ventricular I
dysfunction I
was O
significantly O
lower O
in O
the O
groups O
treated O
with O
25 O
and O
50mg O
/ O
kg O
of O
metformin O
. O

Neuroleptic B
malignant I
syndrome I
induced O
by O
combination O
therapy O
with O
tetrabenazine O
and O
tiapride O
in O
a O
Japanese O
patient O
with O
Huntington B
' I
s I
disease I
at O
the O
terminal O
stage O
of O
recurrent O
breast B
cancer I
. O

We O
herein O
describe O
the O
case O
of O
an O
81 O
- O
year O
- O
old O
Japanese O
woman O
with O
neuroleptic B
malignant I
syndrome I
that O
occurred O
36 O
days O
after O
the O
initiation O
of O
combination O
therapy O
with O
tiapride O
( O
75 O
mg O
/ O
day O
) O
and O
tetrabenazine O
( O
12 O
. O
5 O
mg O
/ O
day O
) O
for O
Huntington B
' I
s I
disease I
. O

To O
the O
best O
of O
our O
knowledge O
, O
the O
occurrence O
of O
neuroleptic B
malignant I
syndrome I
due O
to O
combination O
therapy O
with O
tetrabenazine O
and O
tiapride O
has O
not O
been O
previously O
reported O
. O

A O
63 O
year O
- O
old O
Caucasian O
man O
on O
metoprolol O
200 O
mg O
/ O
day O
for O
stable O
coronary B
artery I
disease I
was O
prescribed O
a O
90 O
- O
day O
course O
of O
oral O
terbinafine O
250 O
mg O
/ O
day O
for O
onychomycosis B
. O

A O
score O
of O
7 O
on O
the O
Naranjo O
adverse B
drug I
reaction I
probability O
scale O
indicates O
a O
probable O
relationship O
between O
the O
patient O
' O
s O
sinus B
bradycardia I
and O
the O
drug O
interaction O
between O
metoprolol O
and O
terbinafine O
. O

Administration O
of O
flutamide O
, O
letrozole O
or O
tamoxifen O
significantly O
impaired B
the I
memory I
in O
intact O
rats O
, O
and O
significantly O
attenuated O
the O
testosterone O
replacement O
in O
improving O
STZ O
- O
and O
castration O
- O
induced O
memory B
impairment I
. O

Standard O
operating O
procedures O
for O
antibiotic O
therapy O
and O
the O
occurrence O
of O
acute B
kidney I
injury I
: O
a O
prospective O
, O
clinical O
, O
non O
- O
interventional O
, O
observational O
study O
. O

INTRODUCTION O
: O
Acute B
kidney I
injury I
( O
AKI B
) O
occurs O
in O
7 O
% O
of O
hospitalized O
and O
66 O
% O
of O
Intensive O
Care O
Unit O
( O
ICU O
) O
patients O
. O

Kinin O
B2 O
receptor O
deletion O
and O
blockage O
ameliorates O
cisplatin O
- O
induced O
acute B
renal I
injury I
. O

Cisplatin O
treatment O
has O
been O
adopted O
in O
some O
chemotherapies O
; O
however O
, O
this O
drug O
can O
induce O
acute B
kidney I
injury I
due O
its O
ability O
to O
negatively O
affect O
renal O
function O
, O
augment O
serum O
levels O
of O
creatinine O
and O
urea O
, O
increase O
the O
acute B
tubular I
necrosis I
score O
and O
up O
- O
regulate O
cytokines O
( O
e O
. O
g O
. O
, O
IL O
- O
1b O
and O
TNF O
- O
a O
) O
. O

Cisplatin O
treatment O
has O
been O
adopted O
in O
some O
chemotherapies O
; O
however O
, O
this O
drug O
can O
induce O
acute B
kidney I
injury I
due O
its O
ability O
to O
negatively O
affect O
renal O
function O
, O
augment O
serum O
levels O
of O
creatinine O
and O
urea O
, O
increase O
the O
acute B
tubular I
necrosis I
score O
and O
up O
- O
regulate O
cytokines O
( O
e O
. O
g O
. O
, O
IL O
- O
1b O
and O
TNF O
- O
a O
) O
. O

To O
examine O
the O
role O
of O
the O
kinin O
B2 O
receptor O
in O
cisplatin O
- O
induced O
acute B
kidney I
injury I
, O
kinin O
B2 O
receptor O
knockout O
mice O
were O
challenged O
with O
cisplatin O
. O

B2 O
receptor O
- O
deficient O
mice O
were O
less O
sensitive O
to O
this O
drug O
than O
the O
WT O
mice O
, O
as O
shown O
by O
reduced O
weight B
loss I
, O
better O
preservation O
of O
kidney O
function O
, O
down O
regulation O
of O
inflammatory O
cytokines O
and O
less O
acute B
tubular I
necrosis I
. O

Thus O
, O
our O
data O
suggest O
that O
the O
kinin O
B2 O
receptor O
is O
involved O
in O
cisplatin O
- O
induced O
acute B
kidney I
injury I
by O
mediating O
the O
necrotic B
process O
and O
the O
expression O
of O
inflammatory O
cytokines O
, O
thus O
resulting O
in O
declined O
renal O
function O
. O

Data O
on O
occurrence O
of O
cataract B
and O
raised B
intraocular I
pressure I
were O
collected O
in O
all O
eyes O
. O

More O
than O
20 O
% O
( O
47 O
. O
61 O
- O
67 O
. O
2 O
% O
) O
reduction O
in O
central O
retinal O
thickness O
was O
noted O
in O
all O
patients O
with O
cystoid B
macular I
edema I
at O
6 O
months O
, O
1 O
year O
, O
2 O
years O
, O
and O
3 O
years O
postimplant O
. O

Adverse O
events O
included O
increased B
intraocular I
pressure I
( O
54 O
. O
5 O
% O
) O
and O
cataract B
formation O
( O
100 O
% O
) O
. O

Absence O
of O
PKC O
- O
alpha O
attenuates O
lithium O
- O
induced O
nephrogenic B
diabetes I
insipidus I
. O

Lithium O
, O
an O
effective O
antipsychotic O
, O
induces O
nephrogenic B
diabetes I
insipidus I
( O
NDI B
) O
in O
40 O
% O
of O
patients O
. O

Acute O
myocardial B
ischemic I
injury I
was O
induced O
in O
rats O
by O
subcutaneous O
injection O
of O
isoproterenol O
( O
85 O
mg O
/ O
kg O
) O
, O
for O
two O
consecutive O
days O
. O

UNASSIGNED O
: O
Our O
previous O
study O
has O
indicated O
that O
prenatal O
caffeine O
exposure O
( O
PCE O
) O
could O
induce O
intrauterine B
growth I
retardation I
( O
IUGR B
) O
of O
offspring O
. O

UNASSIGNED O
: O
Epidemiological O
studies O
of O
1 O
, O
3 O
- O
butadiene O
have O
suggest O
that O
exposures O
to O
humans O
are O
associated O
with O
chronic B
myeloid I
leukemia I
( O
CML B
) O
. O

A O
similar O
pattern O
was O
observed O
for O
follicular B
cell I
lymphoma I
, O
but O
no O
other O
lymphoma B
subtypes O
. O

Effect O
of O
alkylxanthines O
on O
gentamicin O
- O
induced O
acute B
renal I
failure I
in O
the O
rat O
. O

Adenosine O
antagonists O
have O
been O
previously O
shown O
to O
be O
of O
benefit O
in O
some O
ischaemic B
and O
nephrotoxic B
models O
of O
acute B
renal I
failure I
( O
ARF B
) O
. O

In O
the O
present O
study O
, O
the O
effects O
of O
three O
alkylxanthines O
with O
different O
potencies O
as O
adenosine O
antagonists O
8 O
- O
phenyltheophylline O
, O
theophylline O
and O
enprofylline O
, O
were O
examined O
in O
rats O
developing O
acute B
renal I
failure I
after O
4 O
daily O
injections O
of O
gentamicin O
( O
200 O
mg O
kg O
- O
1 O
) O
. O

Isotretinoin O
is O
contraindicated O
in O
pregnancy O
because O
of O
the O
many O
reported O
congenital B
abnormalities I
after O
maternal O
use O
( O
including O
microphthalmos B
, O
orbital O
hypertelorism B
, O
and O
optic B
nerve I
hypoplasia I
) O
. O

Acute B
neurologic I
dysfunction I
after O
high O
- O
dose O
etoposide O
therapy O
for O
malignant B
glioma I
. O

Progressive O
bile B
duct I
injury I
after O
thiabendazole O
administration O
. O

An O
autoimmune O
pathogenesis O
of O
the O
bile B
duct I
destruction I
is O
suggested O
. O

In O
two O
patients O
, O
hypotension B
was O
associated O
with O
severe O
left B
ventricular I
dysfunction I
. O

Despite O
concerns O
of O
fatal O
bone B
marrow I
toxicity I
due O
to O
carbamazepine O
, O
this O
is O
only O
the O
fourth O
documented O
and O
published O
report O
. O

Six O
of O
the O
14 O
patients O
died O
with O
congestive B
heart I
failure I
. O

Congestive B
heart I
failure I
caused O
or O
contributed O
to O
death O
in O
0 O
/ O
32 O
patients O
in O
Group O
1 O
v O
6 O
/ O
52 O
( O
12 O
% O
) O
of O
patients O
in O
Group O
2 O
( O
P O
less O
than O
0 O
. O
25 O
) O
. O

Clinical O
trials O
of O
aminoglycosides O
in O
seriously O
ill O
patients O
indicate O
that O
the O
relative O
risk O
for O
developing O
acute B
renal I
failure I
during O
therapy O
ranges O
from O
8 O
to O
10 O
and O
that O
the O
attributable O
risk O
is O
70 O
% O
to O
80 O
% O
. O

Other O
causes O
of O
acute B
renal I
failure I
, O
such O
as O
shock B
, O
appear O
to O
have O
an O
additive O
effect O
. O

Pilocarpine O
, O
given O
intraperitoneally O
to O
rats O
, O
reproduces O
the O
neuropathological O
sequelae O
of O
temporal B
lobe I
epilepsy I
and O
provides O
a O
relevant O
animal O
model O
for O
studying O
mechanisms O
of O
buildup O
of O
convulsive B
activity O
and O
pathways O
operative O
in O
the O
generalization O
and O
propagation O
of O
seizures B
within O
the O
forebrain O
. O

The O
hearts O
without O
coronary B
artery I
disease I
( O
average O
ejection O
fraction O
of O
this O
group O
62 O
% O
+ O
/ O
- O
10 O
% O
) O
had O
a O
VIP O
concentration O
of O
14 O
. O
1 O
+ O
/ O
- O
7 O
. O
9 O
pg O
/ O
mg O
protein O
, O
and O
this O
was O
greater O
than O
in O
hearts O
of O
the O
patients O
with O
coronary B
disease I
and O
the O
hearts O
of O
patients O
receiving O
a O
transplant O
( O
P O
less O
than O
0 O
. O
05 O
) O
. O

Non O
- O
invasive O
detection O
of O
coronary B
artery I
disease I
by O
body O
surface O
electrocardiographic O
mapping O
after O
dipyridamole O
infusion O
. O

Electrocardiographic O
changes O
after O
dipyridamole O
infusion O
( O
0 O
. O
568 O
mg O
/ O
kg O
/ O
4 O
min O
) O
were O
studied O
in O
41 O
patients O
with O
coronary B
artery I
disease I
and O
compared O
with O
those O
after O
submaximal O
treadmill O
exercise O
by O
use O
of O
the O
body O
surface O
mapping O
technique O
. O

Patients O
were O
divided O
into O
three O
groups O
; O
19 O
patients O
without O
myocardial B
infarction I
( O
non O
- O
MI B
group O
) O
, O
14 O
with O
anterior B
infarction I
( O
ANT B
- I
MI I
) O
and O
eight O
with O
inferior B
infarction I
( O
INF B
- I
MI I
) O
. O

Patients O
were O
divided O
into O
three O
groups O
; O
19 O
patients O
without O
myocardial B
infarction I
( O
non O
- O
MI B
group O
) O
, O
14 O
with O
anterior B
infarction I
( O
ANT B
- I
MI I
) O
and O
eight O
with O
inferior B
infarction I
( O
INF B
- I
MI I
) O
. O

After O
dipyridamole O
, O
ischemic B
ST O
- O
segment O
depression B
( O
0 O
. O
05 O
mV O
or O
more O
) O
was O
observed O
in O
84 O
% O
of O
the O
non O
- O
MI B
group O
, O
29 O
% O
of O
the O
ANT B
- I
MI I
group O
, O
63 O
% O
of O
the O
INF B
- I
MI I
group O
and O
61 O
% O
of O
the O
total O
population O
. O

After O
dipyridamole O
, O
ischemic B
ST O
- O
segment O
depression B
( O
0 O
. O
05 O
mV O
or O
more O
) O
was O
observed O
in O
84 O
% O
of O
the O
non O
- O
MI B
group O
, O
29 O
% O
of O
the O
ANT B
- I
MI I
group O
, O
63 O
% O
of O
the O
INF B
- I
MI I
group O
and O
61 O
% O
of O
the O
total O
population O
. O

Exercise O
- O
induced O
ST O
depression B
was O
observed O
in O
84 O
% O
of O
the O
non O
- O
MI B
group O
, O
43 O
% O
of O
the O
ANT B
- I
MI I
group O
, O
38 O
% O
of O
the O
INF B
- I
MI I
group O
and O
61 O
% O
of O
the O
total O
. O

Exercise O
- O
induced O
ST O
depression B
was O
observed O
in O
84 O
% O
of O
the O
non O
- O
MI B
group O
, O
43 O
% O
of O
the O
ANT B
- I
MI I
group O
, O
38 O
% O
of O
the O
INF B
- I
MI I
group O
and O
61 O
% O
of O
the O
total O
. O

We O
conclude O
that O
the O
dipyridamole O
ECG O
test O
is O
as O
useful O
as O
the O
exercise O
ECG O
test O
for O
the O
assessment O
of O
coronary B
artery I
disease I
. O

It O
is O
concluded O
that O
PAP O
formation O
, O
in O
vivo O
, O
accounts O
, O
at O
least O
in O
part O
, O
for O
APAP O
- O
induced O
renal B
tubular I
necrosis I
. O

These O
complications O
have O
included O
clinical O
deterioration O
and O
intracranial B
vascular I
thrombosis I
in O
patients O
with O
SAH B
, O
arteriolar O
and O
capillary O
fibrin O
thrombi B
in O
patients O
with O
fibrinolytic O
syndromes O
treated O
with O
EACA O
, O
or O
other O
thromboembolic B
phenomena I
. O

Since O
intravascular O
fibrin O
thrombi B
are O
often O
observed O
in O
patients O
with O
fibrinolytic O
disorders O
, O
EACA O
should O
not O
be O
implicated O
in O
the O
pathogenesis O
of O
fibrin O
thrombi B
in O
patients O
with O
disseminated B
intravascular I
coagulation I
or O
other O
" O
consumption B
coagulopathies I
. O
" O
This O
report O
describes O
subtotal O
infarction B
of O
the O
kidney O
due O
to O
thrombosis B
of I
a I
normal I
renal I
artery I
. O

Comparing O
the O
relative O
sensitivity O
to O
central O
depression B
and O
excitation O
revealed O
that O
rats O
were O
least O
likely O
to O
have O
convulsions B
at O
doses O
that O
did O
not O
first O
cause O
loss B
of I
consciousness I
, O
while O
cats O
most O
clearly O
showed O
marked O
central O
excitatory O
actions O
. O

Use O
of O
propranolol O
in O
the O
treatment O
of O
idiopathic B
orthostatic I
hypotension I
. O

Five O
patients O
with O
idiopathic B
orthostatic I
hypotension I
who O
had O
physiologic O
and O
biochemical O
evidence O
of O
severe O
autonomic O
dysfunction O
were O
included O
in O
the O
study O
. O

The O
studies O
suggest O
that O
propranolol O
is O
a O
useful O
drug O
in O
selected O
patients O
with O
severe O
idiopathic B
orthostatic I
hypotension I
. O

Analysis O
of O
site O
of O
infection B
showed O
a O
preponderance O
of O
abdominal B
infections I
in O
liver O
patients O
, O
intrathoracic O
infections B
in O
heart O
patients O
, O
and O
urinary B
tract I
infections I
in O
renal O
patients O
. O

A O
reversible O
toxic B
liver I
damage I
was O
observed O
in O
a O
non O
- O
alcoholic O
woman O
treated O
with O
disulfiram O
. O

Alternating B
sinus I
rhythm I
and O
intermittent O
sinoatrial B
block I
induced O
by O
propranolol O
. O

Alternating B
sinus I
rhythm I
and O
intermittent O
sinoatrial B
( I
S I
- I
A I
) I
block I
was O
observed O
in O
a O
57 O
- O
year O
- O
old O
woman O
, O
under O
treatment O
for O
angina B
with O
80 O
mg O
propranolol O
daily O
. O

Accelerated B
junctional I
rhythms I
during O
oral O
verapamil O
therapy O
. O

This O
study O
examined O
the O
frequency O
of O
atrioventricular O
( O
AV O
) O
dissociation O
and O
accelerated B
junctional I
rhythms I
in O
59 O
patients O
receiving O
oral O
verapamil O
. O

Accelerated B
junctional I
rhythms I
and O
AV O
dissociation O
were O
frequent O
in O
patients O
with O
supraventricular B
tachyarrhythmias I
, O
particularly O
AV O
nodal O
reentry O
. O

The O
first O
case O
is O
of O
an O
acute O
type O
of O
damage O
, O
proven O
by O
rechallenge O
; O
the O
second O
presents O
a O
clinical O
and O
histologic O
picture O
resembling O
chronic B
active I
hepatitis I
, O
with O
spontaneous O
remission O
. O

Hepatitis B
and O
renal B
tubular I
acidosis I
after O
anesthesia O
with O
methoxyflurane O
. O

A O
69 O
- O
year O
- O
old O
man O
operated O
for O
acute B
cholecystitis I
under O
methoxyflurane O
anesthesia O
developed O
postoperatively O
a O
hepatic B
insufficiency I
syndrome I
and O
renal B
tubular I
acidosis I
. O

A O
69 O
- O
year O
- O
old O
man O
operated O
for O
acute B
cholecystitis I
under O
methoxyflurane O
anesthesia O
developed O
postoperatively O
a O
hepatic B
insufficiency I
syndrome I
and O
renal B
tubular I
acidosis I
. O

5 O
patients O
with O
acute B
renal I
failure I
( O
3 O
with O
thrombopenia B
and O
hemolysis B
) O
induced O
by O
the O
reintroduction O
of O
rifampicin O
are O
described O
. O

The O
pattern O
of O
non O
- O
specific O
acute B
tubular I
necrosis I
found O
in O
the O
2 O
biopsied O
patients O
, O
indistinguishable O
from O
that O
of O
ischemic O
origin O
, O
raised O
the O
possibility O
of O
a O
vascular O
- O
mediated O
damage O
. O

It O
is O
the O
third O
urinary B
tract I
cancer I
reported O
in O
association O
with O
cyclophosphamide O
treatment O
for O
nonmalignant O
disease O
. O

The O
case O
shows O
that O
prolonged B
jaw I
rigidity I
and O
myalgia B
may O
occur O
after O
suxamethonium O
in O
patients O
with O
atypical O
cholinesterase O
despite O
pretreatment O
with O
pancuronium O
. O

The O
one O
case O
of O
toxic B
epidermal I
necrolysis I
occurred O
in O
a O
patient O
who O
took O
cephalexin O
. O

Increased O
frequency O
and O
severity O
of O
angio B
- I
oedema I
related O
to O
long O
- O
term O
therapy O
with O
angiotensin O
- O
converting O
enzyme O
inhibitor O
in O
two O
patients O
. O

Adverse O
reactions O
to O
drugs O
are O
well O
recognized O
as O
a O
cause O
of O
acute O
or O
chronic O
urticaria B
, O
and O
angio B
- I
oedema I
. O

Angiotensin O
- O
converting O
enzyme O
( O
ACE O
) O
inhibitors O
, O
used O
to O
treat O
hypertension B
and O
congestive B
heart I
failure I
, O
were O
introduced O
in O
Europe O
in O
the O
middle O
of O
the O
eighties O
, O
and O
the O
use O
of O
these O
drugs O
has O
increased O
progressively O
. O

Soon O
after O
the O
introduction O
of O
ACE O
inhibitors O
, O
acute O
bouts O
of O
angio B
- I
oedema I
were O
reported O
in O
association O
with O
the O
use O
of O
these O
drugs O
. O

We O
wish O
to O
draw O
attention O
to O
the O
possibility O
of O
adverse O
reactions O
to O
ACE O
inhibitors O
after O
long O
- O
term O
use O
and O
in O
patients O
with O
pre O
- O
existing O
angio B
- I
oedema I
. O

S O
- O
312 O
, O
S O
- O
312 O
- O
d O
, O
but O
not O
S O
- O
312 O
- O
l O
, O
L O
- O
type O
calcium O
channel O
antagonists O
, O
showed O
anticonvulsant O
effects O
on O
the O
audiogenic B
tonic I
convulsions I
in O
DBA O
/ O
2 O
mice O
; O
and O
their O
ED50 O
values O
were O
18 O
. O
4 O
( O
12 O
. O
8 O
- O
27 O
. O
1 O
) O
mg O
/ O
kg O
, O
p O
. O
o O
. O
and O
15 O
. O
0 O
( O
10 O
. O
2 O
- O
23 O
. O
7 O
) O
mg O
/ O
kg O
, O
p O
. O
o O
. O
, O
respectively O
, O
while O
that O
of O
flunarizine O
was O
34 O
. O
0 O
( O
26 O
. O
0 O
- O
44 O
. O
8 O
) O
mg O
/ O
kg O
, O
p O

The O
patient O
had O
no O
history O
of O
underlying O
ischaemic B
heart I
disease I
or O
Prinzmetal B
' I
s I
angina I
. O

Indications O
for O
transplantation O
were O
idiopathic B
cardiomyopathy I
( O
52 O
% O
) O
, O
congenital B
heart I
disease I
( O
35 O
% O
) O
with O
and O
without O
prior O
repair O
( O
71 O
% O
and O
29 O
% O
, O
respectively O
) O
, O
hypertrophic B
cardiomyopathy I
( O
5 O
% O
) O
, O
valvular B
heart I
disease I
( O
3 O
% O
) O
, O
and O
doxorubicin O
cardiomyopathy B
( O
5 O
% O
) O
. O

Indications O
for O
transplantation O
were O
idiopathic B
cardiomyopathy I
( O
52 O
% O
) O
, O
congenital B
heart I
disease I
( O
35 O
% O
) O
with O
and O
without O
prior O
repair O
( O
71 O
% O
and O
29 O
% O
, O
respectively O
) O
, O
hypertrophic B
cardiomyopathy I
( O
5 O
% O
) O
, O
valvular B
heart I
disease I
( O
3 O
% O
) O
, O
and O
doxorubicin O
cardiomyopathy B
( O
5 O
% O
) O
. O

It O
was O
characterized O
by O
the O
onset O
of O
fever B
, O
diarrhea B
, O
shock B
, O
pulmonary B
edema I
, O
acute B
renal I
failure I
, O
metabolic B
acidosis I
, O
weight B
gain I
and O
leukocytosis B
. O

The O
ischemia B
probably O
induced O
by O
coronary B
artery I
spasm I
was O
reversed O
by O
nitroglycerin O
and O
calcium O
blocking O
agents O
. O

Milk B
- I
alkali I
syndrome I
was O
first O
described O
70 O
years O
ago O
in O
the O
context O
of O
the O
treatment O
of O
peptic B
ulcer I
disease I
with O
large O
amounts O
of O
calcium O
and O
alkali O
. O

Encephalopathy B
during O
amitriptyline O
therapy O
: O
are O
neuroleptic B
malignant I
syndrome I
and O
serotonin B
syndrome I
spectrum O
disorders O
? O

This O
patient O
could O
have O
been O
diagnosed O
as O
having O
either O
neuroleptic B
malignant I
syndrome I
( O
NMS B
) O
or O
serotonin B
syndrome I
( O
SS B
) O
. O

In O
the O
presence O
of O
coronary B
artery I
stenosis I
, O
3 O
- O
min O
periods O
of O
intracoronary O
ISO O
infusion O
( O
10 O
ng O
/ O
kg O
/ O
min O
) O
increased O
heart O
rate O
and O
maximal O
rate O
of O
left O
ventricular O
pressure O
rise O
, O
which O
resulted O
in O
a O
decrease O
in O
percentage O
segmental O
shortening O
and O
ST O
- O
segment O
elevation O
of O
the O
epicardial O
electrocardiogram O
. O

This O
study O
prospectively O
evaluated O
the O
clinical O
efficacy O
, O
the O
incidence O
of O
torsades B
de I
pointes I
, O
and O
the O
presumable O
risk O
factors O
for O
torsades B
de I
pointes I
in O
patients O
treated O
with O
d O
, O
l O
- O
sotalol O
for O
sustained O
ventricular B
tachyarrhythmias I
. O

This O
study O
prospectively O
evaluated O
the O
clinical O
efficacy O
, O
the O
incidence O
of O
torsades B
de I
pointes I
, O
and O
the O
presumable O
risk O
factors O
for O
torsades B
de I
pointes I
in O
patients O
treated O
with O
d O
, O
l O
- O
sotalol O
for O
sustained O
ventricular B
tachyarrhythmias I
. O

Eighty O
- O
one O
consecutive O
patients O
( O
54 O
with O
coronary B
artery I
disease I
, O
and O
20 O
with O
dilated B
cardiomyopathy I
) O
with O
inducible O
sustained O
ventricular B
tachycardia I
or O
ventricular B
fibrillation I
received O
oral O
d O
, O
l O
- O
sotalol O
to O
prevent O
induction O
of O
the O
ventricular B
tachyarrhythmia I
. O

Four O
( O
5 O
% O
) O
patients O
had O
from O
torsades B
de I
pointes I
during O
the O
initial O
oral O
treatment O
with O
d O
, O
l O
- O
sotalol O
. O

Neither O
ECG O
[ O
sinus O
- O
cycle O
length O
( O
SCL O
) O
, O
QT O
or O
QTc O
interval O
, O
or O
U O
wave O
] O
nor O
clinical O
parameters O
identified O
patients O
at O
risk O
for O
torsades B
de I
pointes I
. O

However O
, O
the O
oral O
dose O
of O
d O
, O
l O
- O
sotalol O
was O
significantly O
lower O
in O
patients O
with O
torsades B
de I
pointes I
( O
200 O
+ O
/ O
- O
46 O
vs O
. O
328 O
+ O
/ O
- O
53 O
mg O
/ O
day O
; O
p O
= O
0 O
. O
0017 O
) O
. O

Risk O
factors O
associated O
with O
the O
development O
of O
torsades B
de I
pointes I
were O
the O
appearance O
of O
an O
U O
wave O
( O
p O
= O
0 O
. O
049 O
) O
, O
female O
gender O
( O
p O
= O
0 O
. O
015 O
) O
, O
and O
significant O
dose O
- O
corrected O
changes O
of O
SCL O
, O
QT O
interval O
, O
and O
QTc O
interval O
( O
p O
< O
0 O
. O
05 O
) O
. O

One O
female O
patient O
with O
stable O
cardiac B
disease I
had O
recurrent O
torsades B
de I
pointes I
after O
2 O
years O
of O
successful O
treatment O
with O
d O
, O
l O
- O
sotalol O
. O

Torsades B
de I
pointes I
occurred O
early O
during O
treatment O
even O
with O
low O
doses O
of O
oral O
d O
, O
l O
- O
sotalol O
. O

Pronounced O
changes O
in O
the O
surface O
ECG O
( O
cycle O
length O
, O
QT O
, O
and O
QTc O
) O
in O
relation O
to O
the O
dose O
of O
oral O
d O
, O
l O
- O
sotalol O
might O
identify O
a O
subgroup O
of O
patients O
with O
an O
increased O
risk O
for O
torsades B
de I
pointes I
. O

Other O
ECG O
parameters O
before O
the O
application O
of O
d O
, O
l O
- O
sotalol O
did O
not O
identify O
patients O
at O
increased O
risk O
for O
torsades B
de I
pointes I
. O

This O
report O
describes O
unique O
contrast O
enhancement O
of O
the O
white O
matter O
on O
T1 O
- O
weighted O
magnetic O
resonance O
images O
of O
two O
patients O
with O
disseminated O
necrotizing O
leukoencephalopathy B
, O
which O
developed O
from O
acute B
lymphoblastic I
leukemia I
treated O
with O
high O
- O
dose O
methotrexate O
. O

Necropsy O
of O
the O
first O
case O
revealed O
loss B
of I
myelination I
and O
necrosis B
of O
the O
white O
matter O
. O

Thrombotic B
complications O
in O
acute B
promyelocytic I
leukemia I
during O
all O
- O
trans O
- O
retinoic O
acid O
therapy O
. O

A O
case O
of O
acute B
renal I
failure I
, O
due O
to O
occlusion B
of I
renal I
vessels I
in O
a O
patient O
with O
acute B
promyelocytic I
leukemia I
( O
APL B
) O
treated O
with O
all O
- O
trans O
- O
retinoic O
acid O
( O
ATRA O
) O
and O
tranexamic O
acid O
has O
been O
described O
recently O
. O

A O
case O
of O
acute B
renal I
failure I
, O
due O
to O
occlusion B
of I
renal I
vessels I
in O
a O
patient O
with O
acute B
promyelocytic I
leukemia I
( O
APL B
) O
treated O
with O
all O
- O
trans O
- O
retinoic O
acid O
( O
ATRA O
) O
and O
tranexamic O
acid O
has O
been O
described O
recently O
. O

We O
report O
a O
case O
of O
acute B
renal I
failure I
in O
an O
APL B
patient O
treated O
with O
ATRA O
alone O
. O

After O
10 O
days O
of O
treatment O
, O
he O
developed O
acute B
renal I
failure I
that O
was O
completely O
reversible O
after O
complete O
remission O
of O
APL B
was O
achieved O
and O
therapy O
discontinued O
. O

Dehydrated B
rats O
regularly O
develop O
acute B
renal I
failure I
following O
single O
injection O
of O
aminoglycoside O
antibiotics O
combined O
with O
dextran O
or O
of O
antibiotics O
only O
. O

She O
had O
developed O
a O
severe O
acute O
major B
depression I
disorder I
almost O
immediately O
thereafter O
, O
possibly O
related O
to O
the O
use O
of O
a O
serotonin O
antagonist O
. O

Hyperosmolar B
nonketotic I
coma I
precipitated O
by O
lithium O
- O
induced O
nephrogenic B
diabetes I
insipidus I
. O

Hyperosmolar B
nonketotic I
coma I
precipitated O
by O
lithium O
- O
induced O
nephrogenic B
diabetes I
insipidus I
. O

After O
recovery O
from O
hyperglycaemia B
, O
he O
remained O
polyuric B
despite O
normal O
blood O
glucose O
concentrations O
; O
water O
deprivation O
testing O
indicated O
nephrogenic B
diabetes I
insipidus I
, O
likely O
to O
be O
lithium O
- O
induced O
. O

We O
hypothesize O
that O
when O
this O
man O
developed O
type B
2 I
diabetes I
, O
chronic O
polyuria B
due O
to O
nephrogenic B
diabetes I
insipidus I
was O
sufficient O
to O
precipitate O
hyperosmolar O
dehydration B
. O

We O
hypothesize O
that O
when O
this O
man O
developed O
type B
2 I
diabetes I
, O
chronic O
polyuria B
due O
to O
nephrogenic B
diabetes I
insipidus I
was O
sufficient O
to O
precipitate O
hyperosmolar O
dehydration B
. O

OBJECTIVE O
: O
We O
describe O
the O
unique O
CT O
features O
of O
ureteric B
calculi I
in O
six O
HIV B
- I
infected I
patients O
receiving O
indinavir O
, O
the O
most O
commonly O
used O
HIV O
protease O
inhibitor O
, O
which O
is O
associated O
with O
an O
increased O
incidence O
of O
urolithiasis B
. O

Neuroleptic B
malignant I
syndrome I
and O
methylphenidate O
. O

A O
1 O
- O
year O
- O
old O
female O
presented O
with O
neuroleptic B
malignant I
syndrome I
probably O
caused O
by O
methylphenidate O
. O

She O
had O
defects O
in O
the O
supratentorial O
brain O
including O
the O
basal O
ganglia O
and O
the O
striatum O
( O
multicystic B
encephalomalacia I
) O
due O
to O
severe O
perinatal O
hypoxic B
- I
ischemic I
encephalopathy I
, O
which O
was O
considered O
to O
be O
a O
possible O
predisposing O
factor O
causing O
neuroleptic B
malignant I
syndrome I
. O

This O
is O
the O
first O
reported O
patient O
with O
neuroleptic B
malignant I
syndrome I
probably O
caused O
by O
methylphenidate O
. O

